ADMA Biologics's book value per share for the quarter that ended in Mar. 2026 was $1.68.
During the past 12 months, ADMA Biologics's average Book Value Per Share Growth Rate was 7.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 43.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 19.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of ADMA Biologics was 77.00% per year. The lowest was -57.80% per year. And the median was 15.70% per year.
ADMA Biologics's current price is $9.21. Its book value per share for the quarter that ended in Mar. 2026 was $1.68. Hence, today's PB Ratio of ADMA Biologics is 5.48.
During the past 13 years, the highest P/B Ratio of ADMA Biologics was 25.82. The lowest was 1.41. And the median was 5.79.
ADMA Biologics (NAS:ADMA) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
ADMA Biologics Book Value per Share Related Terms
ADMA Biologics Book Value per Share Historical Data
* Premium members only.
The historical data trend for ADMA Biologics's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADMA vs ZLAB, HRMY, STOK: Book Value per Share Comparison
For the Biotechnology subindustry, ADMA Biologics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADMA Biologics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADMA Biologics's PB Ratio distribution charts can be found below:
* The bar in red indicates where ADMA Biologics's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADMA Biologics (ADMA) has a Book Value per Share of $1.68 as of Mar. 2026. Book value per share gives the per-share value of a company's stockholder equity. View historical data on ADMA Biologics and its competitors.
Is ADMA Biologics' Book Value per Share too high?
ADMA Biologics' current Book Value per Share is $1.68. Overall, ADMA Biologics has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ADMA Biologics' Book Value per Share compare to ZLAB and HRMY?
ADMA Biologics' Book Value per Share of $1.68 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Biotechnology company?
A good Book Value per Share depends on the Biotechnology industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on ADMA Biologics and its competitors. ADMA Biologics's current Book Value per Share is $1.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADMA Biologics stock overvalued right now?
Based on GuruFocus' analysis, ADMA Biologics (ADMA) is currently considered Significantly Undervalued. The stock's GF Value™ is $18.03, compared to a current price of $9.21 — trading 48.9% below its estimated fair value. The current Book Value per Share is $1.68. ADMA Biologics' overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For ADMA Biologics (ADMA), the current Book Value per Share is $1.68 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADMA Biologics (ADMA) Overvalued in 2026?
Based on GuruFocus' analysis, ADMA Biologics stock appears to be undervalued.
The current stock price of $9.21 is trading 48.9% below its estimated GF Value™ of $18.03.
GuruFocus considers ADMA Biologics to be Significantly Undervalued.
Key valuation signals for ADMA:
Book Value per Share: $1.68
GF Value™: $18.03 vs. price of $9.21 (48.9% below fair value)
No single metric tells the full story. See the ADMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
64GF Score
Get the complete analysis for ADMA
Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADMA has been successfully added to your 
